IGC Pharma, Inc. (IGC)
0.272
+0.01
(+1.91%)
USD |
NYAM |
Sep 16, 16:00
0.27
0.00 (0.00%)
After-Hours: 20:00
IGC Pharma Enterprise Value : 28.59M for Sept. 16, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 16, 2026 | 28.59M |
| September 15, 2026 | 28.06M |
| September 14, 2026 | 28.94M |
| September 11, 2026 | 29.26M |
| September 10, 2026 | 29.71M |
| September 09, 2026 | 29.56M |
| September 08, 2026 | 30.42M |
| September 04, 2026 | 31.25M |
| September 03, 2026 | 31.30M |
| September 02, 2026 | 31.03M |
| September 01, 2026 | 31.12M |
| August 31, 2026 | 31.37M |
| August 28, 2026 | 32.48M |
| August 27, 2026 | 34.93M |
| August 26, 2026 | 32.24M |
| August 25, 2026 | 31.92M |
| August 24, 2026 | 31.51M |
| August 21, 2026 | 32.27M |
| August 20, 2026 | 29.12M |
| August 19, 2026 | 29.95M |
| August 18, 2026 | 29.86M |
| August 17, 2026 | 29.40M |
| August 14, 2026 | 31.23M |
| August 13, 2026 | 30.84M |
| August 12, 2026 | 30.01M |
| Date | Value |
|---|---|
| August 11, 2026 | 29.51M |
| August 10, 2026 | 28.12M |
| August 07, 2026 | 27.01M |
| August 06, 2026 | 26.32M |
| August 05, 2026 | 26.54M |
| August 04, 2026 | 26.13M |
| August 03, 2026 | 25.83M |
| July 31, 2026 | 26.23M |
| July 30, 2026 | 26.28M |
| July 29, 2026 | 25.31M |
| July 28, 2026 | 27.25M |
| July 27, 2026 | 27.66M |
| July 24, 2026 | 27.77M |
| July 23, 2026 | 27.87M |
| July 22, 2026 | 28.37M |
| July 21, 2026 | 28.08M |
| July 20, 2026 | 28.17M |
| July 17, 2026 | 27.36M |
| July 16, 2026 | 26.98M |
| July 15, 2026 | 28.17M |
| July 14, 2026 | 28.07M |
| July 13, 2026 | 27.96M |
| July 10, 2026 | 28.59M |
| July 09, 2026 | 29.30M |
| July 08, 2026 | 28.90M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Cocrystal Pharma, Inc. | 14.82M |
| CNBX Pharmaceuticals, Inc. | 1.305M |
| GB Sciences, Inc. | -- |
| Arvinas, Inc. | -26.85M |
| Fulcrum Therapeutics, Inc. | -24.44M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -2.936M |
| Revenue (Quarterly) | 0.265M |
| Total Expenses (Quarterly) | 3.201M |
| EPS Diluted (Quarterly) | -0.0293 |
| Gross Profit Margin (Quarterly) | 2.64% |
| Profit Margin (Quarterly) | -1.11K% |
| Earnings Yield | -30.00% |
| Normalized Earnings Yield | -30.00 |